Meeting
2017 ASCO Annual Meeting
First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
Authors
Wolfgang Janni
University of Ulm, Ulm, Germany
Wolfgang Janni , Howard A. Burris III, Kimberly L. Blackwell , Lowell L. Hart , Arlene Chan , Arnd Nusch , Olga Nikolaevna Burdaeva , Emilio Alba , Denise A. Yardley , Thomas Denis Bachelot , Miguel J. Gil Gil , Donald A. Richards , Joseph A. Sparano , Joseph Gergi Kattan , Hugues Pierre Bourgeois , Fadi Rafic El Karak , Bhuvaneswari Ramaswamy , Santosh C. Sutradhar , Michelle Kristine Miller , Pier Franco Conte
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT01958021
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1047)
DOI
10.1200/JCO.2017.35.15_suppl.1047
Abstract #
1047
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.
First Author: Joyce O'Shaughnessy
Poster
2017 ASCO Annual Meeting
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).
First Author: Gabriel N. Hortobagyi
Poster
2018 ASCO Annual Meeting
First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.
First Author: Gabriel N. Hortobagyi
Poster
2015 ASCO Annual Meeting
Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).
First Author: Dennis J. Slamon